195 related articles for article (PubMed ID: 32479983)
21. The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel.
Pakarinen PI; Lähteenmäki P; Lehtonen E; Reima I
Hum Reprod; 1998 Jul; 13(7):1846-53. PubMed ID: 9740437
[TBL] [Abstract][Full Text] [Related]
22. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
23. Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium.
Gomes MK; Rosa-e-Silva JC; Garcia SB; de Sá Rosa-e-Silva AC; Turatti A; Vieira CS; Ferriani RA
Hum Reprod; 2009 Nov; 24(11):2736-45. PubMed ID: 19661125
[TBL] [Abstract][Full Text] [Related]
24. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study.
Akesson E; Gallos ID; Ganesan R; Varma R; Gupta JK
Acta Obstet Gynecol Scand; 2010 Mar; 89(3):393-8. PubMed ID: 20199355
[TBL] [Abstract][Full Text] [Related]
26. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel.
Hurskainen R; Salmi A; Paavonen J; Teperi J; Rutanen E
Mol Hum Reprod; 2000 Nov; 6(11):1013-8. PubMed ID: 11044464
[TBL] [Abstract][Full Text] [Related]
27. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
28. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery.
Rutanen EM
Hum Reprod; 2000 Aug; 15 Suppl 3():173-81. PubMed ID: 11041233
[TBL] [Abstract][Full Text] [Related]
30. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
32. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
[TBL] [Abstract][Full Text] [Related]
33. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
34. Endometrial effects of intrauterine levonorgestrel.
Guttinger A; Critchley HO
Contraception; 2007 Jun; 75(6 Suppl):S93-8. PubMed ID: 17531624
[TBL] [Abstract][Full Text] [Related]
35. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system.
Engemise SL; Willets JM; Taylor AH; Emembolu JO; Konje JC
Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):101-6. PubMed ID: 21470761
[TBL] [Abstract][Full Text] [Related]
36. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.
Varila E; Wahlström T; Rauramo I
Fertil Steril; 2001 Nov; 76(5):969-73. PubMed ID: 11704119
[TBL] [Abstract][Full Text] [Related]
37. Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
Sletten ET; Arnes M; Vereide AB; Ørbo A
Anticancer Res; 2018 May; 38(5):2883-2889. PubMed ID: 29715112
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
Wan YL; Holland C
Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
